• Source: YCT529

    • YCT529 is a drug which acts as a potent and selective antagonist of the vitamin A receptor retinoic acid receptor alpha (RAR-α). In studies on mice it produced a 99% reduction in sperm production, and it has proceeded to early stage human clinical trials as a potential male contraceptive.
    The vitamin A signalling system plays a number of important roles in bodily systems, such as the immune system. “It seems to me inherently unlikely that a compound with such activity would be free of side effects,” says Richard Sharpe, of the University of Edinburgh.


    See also


    Adjudin
    CDD-2807
    Dimethandrolone undecanoate
    JQ1
    TDI-11861


    References

Kata Kunci Pencarian: